Thank and you, afternoon Rob, good everyone.
patients activity, that The with Let outlining end It of XXXX. the line for enroll of tight, our quarter be the clinical the Overall, IMPALA-X, XX we study. data by optimistic. and about IMPALA, second of will X U.S. the quarter IMPALA the with week we XX IMPALA-X the the with in for XXX study, end during This study the remain second need the final IMPALA-X, to are pipeline an good sites, guidance have X were of the with including patients enrolled total additional enrolled us the opportunity we study. as with increase eight subjects the a but our study XX this a maintain current current enrolled begin four to patient Accordingly, as the maintain completing of of completing remaining sites of and IMPALA a expected, contributing At extension and years. eligible enrolment, update studies. also quarter. screenings. QX. another XX patients seeing had also of quarter one at to total the we of whom pivotal the ongoing a top guidance left Molgradex XX new the to enrolled in for new enrolment study with offers there continue to of of had we our we QX, up AVAIL is open-label of patients end to patients end while In Molgradex for today, additional Indeed, an subjects shortly. progress patients date, treatment of our happening me An be we for the update rate. for maintained to with into enroll The schedule continued per aPAP steady OPTIMA, Phase and an next two of enrolled had our on are Subsequently, the QX. enrolment the steady XX we clinical as rate of
say Now we high enrolment into our and/or portion believe BLA of high study interest of in participation study on designation positive gives with investments fast-track timely as IMPALA-X the that would breakthrough results late with a make Molgradex with have XXXX in important commercial the level encouraged We the our the Accordingly, into that open approval required the feedback, as the study. a study, driven activities more label I treatment the launch launch. rates after confidence in investigator by IMPALA-X we FDA successful outcome for by insight of noted, the into the Rob the commercial first satisfaction should a for Molgradex the eligible in external IMPALA started the intensively invest well the Molgradex. of required activities in IMPALA-study, of therapy robust or with as as in are well and core early facilitate very very as commercial an staff, We for launch commercial leadership targeted and submission XXXX. in anticipated in Molgradex half believe to XXXX
strong to and X of OPTIMA we in update treatment the NTM quarter four had enrollment. study Phase the you of QX, in like XX the during on have the enrolled. enrolled with study infection. patients Molgradex we our lung progress we the first March, would I ending an for We initiated At patients, XX to that, the enrolled of second Subsequent continued additional quarter, patients. end Next,
new of pipeline provide quarter. rate, now this XXXX. of expect continue maintain year XX QX plan healthy we of a results and all QX interim screenings to screening definitively and more the low guidance our very to this enrolment of of in in We patients end With the of completing top we results failure by line
as a reminder, patients NTM study our just ongoing is Now, CF. focused on have OPTIMA do not that
CF of study, the NTM the of progression has abscessus-infected the After the in the CF encouraging been a Dr. we open-label lung highly publication Wieland's to community a study in X study. culture subjects, as towards individuals and in conversion NTM results of Phase However, infection. chronic CF-affected There have clinical subjects. both interest M. tremendous of Molgradex broader working range our planned which been patients, in with included new eventual program on a of
XX collaboration CF with in the follow-up will with three of the Mycobacterium close chronic foundation infection. study in network or their for now next abscesses with patient treatment start mycobacterial of are and U.S. comprise weeks, XX complex well a our patients This XX weeks. period and enroll study are a anticipated year. and study preparations QX in avium an underway subgroups will new The We NTM of
with naive the we the culture Molgradex be group sputum two patients Similar primary endpoint will NTM to a conversion addition study, the treatment have OPTIMA, the OPTIMA of we will also in have third In treated negative. to groups monotherapy. consisting who to be
negative durability Secondary smear culture conversion, of to microbiology bacterial and consistency endpoints conversion include NTM burden. and quantitative
number change in studies, typical addition, score will symptom a In function pulmonary have CF index. for of respiratory body test, endpoints and we mass clinical including
on Phase study end more and Now, I currently conducted development clinical XX at initiated lastly, an and is pivotal September study X year, front, last sites with U.S. the across the provide Canada. the We being at update AeroVanc. on of AVAIL than the of you will clinical our
we subjects and quarter. of enrolled XXX. had focused of subjects, it completed enrolment of age. of population subjects out are second known of end XX the the we total primary an Subsequent the analysis second the the population by quarter younger that, and subjects, of whom enrolment XX the the been years a comprises solely We to end quarter of the of XXX to ending in This As enrolled during of that’s have of XX the the XXX quarter, X on the QX, last with subjects. planned enrolled subjects we adult total XX additional full XX is
our of targets, second guidance XXXX. remain expected will enrolment line in the optimistic in in the quarter XXXX that completion of we continue AVAIL first to of meet studies, therefore our As we half data our and maintain enrolment we all of with top for
have to we gear like exciting changing developments on. focus the Now I some from current would future, the pipeline to
appointment our a underlines we’re which disease like range highlight to innovation First, In to becoming our with commitment of orphan products. our context, of excited of diseases, lung the would Bruce exploratory pipeline, vision launch Dr. advisor. strong of and also Montgomery orphan the I extremely acquisition a lung a growth as by covering the of strategic broad pipeline through innovative product and company, this
who inhaled are Dr. TOBI diseases of pioneer and a was all now For those and therapies. antibiotics. inhaled with in He of key of accomplished you most one of the entrepreneurs are familiar Montgomery and force is development cornerstones Pulmozyme, a lung field, the behind leading important the field which of of driving Cayston, CF less our orphan
quite our some input on of development providing informal In time terms he has for and programs, AeroVanc already the now. of Molgradex been
expert providing of growth. future development, identify our key help fuel input our products to high would our that focus In or to ongoing evaluate impact addition will area new be and collaboration indications for a clinical
to transformational our into to $XX Our million invest cost with per which proof-of-concept for plan $X our growth. modest exploratory year is collectively be and future million up initially could pipeline, to
In-vitro Cardeas. internal antibiotic Pharma. which already in Gram-positive existing is a exploratory The exploratory acquisition good nebulizer combination our programs. effect new X first ready and the innovation amikacin/fosfomycin product Whereas solution, candidate bacteria, optimized through pipeline with against Our acquired of demonstrated multidrug-resistant amikacin/fosfomycin formulation been for NTM of the is program a antibiotics a example extensively has is tested from in into delivery within studies our patented studies broad-spectrum fact by innovation this including powerful a two Gram-negative Cardeas bacteria. Phase
pneumonia was and failed encouraging antimicrobial and its safety a the product Although an ventilator-associated the the in primary profile. product tolerability to efficacy meet excellent had endpoint study,
apply product antimicrobial infections the to We patients, intrigued financial finish we resistant certainly believe in review the to would also anti-infective Dave, intend the immune already This well-established the system context, the to certainly the in of imminent dual system system lack has the of shift most of We this the immunotherapy. infectious in of to high-note or also in call of We The a strategy chronic innate without to infection. immune I expansion quarter about patients form treatments, most significant program We fight as infection antibiotics, who is could applying basically refractory are already drug is paradigm bacterial infections. represent approach direct that this and our as currently options, either the treatment intrigued to are local broader with lung stimulation with and administered on immune of NTM. with similar results. now the lung potential an In refer second as will been hospitalized both enhancing focus Molgradex. adequate system and the believe harnessing hand combining a in immune locally this highly to power like for the well diseases. therapeutic of our over that in oncology treatment redirect we we’re will
